Published in Health and Medicine Week, December 8th, 2003
Depomed also announced that it has been issued an additional patent on its proprietary, controlled-release Gastric Retention (GR) drug delivery system, on which both Metformin GR and Ciprofloxacin GR are based. Depomed anticipates completing data analyses and announcing the results of both phase III clinical trials in the first quarter of 2004, and filing New...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.